Cellectar Biosciences, Inc.
CLRB
$3.08
-$0.17-5.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 8.80% | -36.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.32% | -19.66% | |||
| Operating Income | -17.32% | 19.66% | |||
| Income Before Tax | -19.16% | 18.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.16% | 18.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.16% | 18.43% | |||
| EBIT | -17.32% | 19.66% | |||
| EBITDA | -17.56% | 19.79% | |||
| EPS Basic | 8.30% | 58.50% | |||
| Normalized Basic EPS | 8.30% | 58.50% | |||
| EPS Diluted | 8.60% | 58.41% | |||
| Normalized Diluted EPS | 8.30% | 58.50% | |||
| Average Basic Shares Outstanding | 29.94% | 96.54% | |||
| Average Diluted Shares Outstanding | 29.94% | 96.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||